University Hospital of Leipzig
Welcome,         Profile    Billing    Logout  
 8 Trials 
28 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Franke, Georg-Nikolaus
IDUNN, NCT04629833 / 2019-001462-15: Treatment of Steroid-Refractory Acute Graft-versus-host Disease with Mesenchymal Stromal Cells Versus Best Available Therapy

Recruiting
3
210
Europe
MC0518, BAT
medac GmbH
Steroid-refractory Acute Graft-versus-host Disease
08/27
08/30
OASIS, NCT05101187: Olorofim Aspergillus Infection Study

Recruiting
3
225
Europe, Canada, Japan, US, RoW
Olorofim, Olorofim (F901318), AmBisome®, AmBisome® (liposomal amphotericin B)
F2G Biotech GmbH, Iqvia Pty Ltd, Shionogi
Invasive Aspergillosis
09/25
11/26
MO-TRANS, NCT05429632 / 2021-002864-36: Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

Active, not recruiting
3
249
Europe, Japan, US, RoW
mocravimod
Priothera SAS, Priothera S.A.S.
Adult Acute Myeloid Leukemia
11/25
11/25
MYLOX-1, NCT04679870 / 2020-003087-45: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral GB2064 in Participants With Myelofibrosis

Active, not recruiting
2
21
Europe, US, RoW
GB2064
Galecto Biotech AB, OPIS s.r.l
Myelofibrosis
12/23
06/26
TAK-620-5010, NCT06615921: A Study of Maribavir in Adults With Post-transplant Cytomegalovirus (CMV) Infection

Recruiting
N/A
150
Europe, RoW
No Intervention
Takeda
Cytomegalovirus (CMV)
04/25
04/25
Classen, Joseph
STRIDES, NCT05490563: - a Clinical Research Study of an Investigational New Drug to Treat Spinocerebellar Ataxia

Terminated
2/3
23
Europe, US, RoW
SLS-005, Placebo
Seelos Therapeutics, Inc.
Spinocerebellar Ataxia Type 3
11/23
11/23
PROSPER, NCT06355531: A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP)

Recruiting
2
220
Europe, US
FNP-223, Placebo
Ferrer Internacional S.A.
Progressive Supranuclear Palsy
11/26
11/26
Vancheri, C
CORAL, NCT05964335: Cough Reduction in IPF with Nalbuphine ER

Recruiting
2
160
Europe, Canada, RoW
nalbuphine ER 27 mg, Active, Placebo, nalbuphine ER 54 mg, nalbuphine ER 108 mg
Trevi Therapeutics
Idiopathic Pulmonary Fibrosis
04/25
04/25
Bernal, Vanesa
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( )

Recruiting
3
1000
Europe, Canada, US, RoW
IVA337, Lanifibranor, Placebo
Inventiva Pharma
NASH - Nonalcoholic Steatohepatitis
09/25
09/26
DHELIVER, NCT04229901: Study to Evaluate the Efficacy and Safety of HepaStem in Patients With Acute on Chronic Liver Failure (ACLF)

Terminated
2
133
Europe, RoW
HepaStem, Placebo
Cellaion SA
Acute on Chronic Liver Failure
05/24
05/24
Herling, Marco
CADENZA, NCT03386513 / 2018-003210-40: Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN

Hourglass Jan 2024 - Dec 2024 : Top-line data from cohort 6 for 1L BPCDN
Active, not recruiting
1/2
179
Europe, US
IMGN632
AbbVie
Blastic Plasmacytoid Dendritic Cell Neoplasm, Myeloproliferative Neoplasm
09/23
12/26
Petros, Sirak
ARISS, NCT03869385: Albumin Replacement Therapy in Septic Shock

Terminated
3
440
Europe
Albutein® 200 g/L or Plasbumin® 20, Human Albumin 20%
Jena University Hospital, German Research Foundation, Instituto Grifols, S.A., University Hospital Goettingen, SepNet - Critical Care Trials Group, Center for Sepsis Control and Care, Germany
Septic Shock
07/22
06/23
PROCYSS, NCT04963920: A RCT to Assess the Performance of CytoSorb for Shock Reversal in Patients With Vasoplegic Septic Shock

Recruiting
N/A
260
Europe
Cytosorb® 300 ml
CytoSorbents Europe GmbH, BRAHMS GmbH, MedInnovation GmbH
Septic Shock
02/25
05/25
Meilick, Bianca
STRIDES, NCT05490563: - a Clinical Research Study of an Investigational New Drug to Treat Spinocerebellar Ataxia

Terminated
2/3
23
Europe, US, RoW
SLS-005, Placebo
Seelos Therapeutics, Inc.
Spinocerebellar Ataxia Type 3
11/23
11/23
Merz, Maximilian
iinnovate-1, NCT03215030 / 2021-006038-37: A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma

Completed
1/2
272
Europe, Canada, Japan, US, RoW
Modakafusp alfa, TAK-573, TEV-48573, Dexamethasone
Takeda, Takeda Development Center Americas, Inc.
Multiple Myeloma
07/24
11/24
Raab
MajesTEC-4, NCT05243797 / 2021-002531-27: Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

Recruiting
3
1594
Europe, Canada, US, RoW
Teclistamab, JNJ-64007957, Lenalidomide
Stichting European Myeloma Network, Janssen Pharmaceutica
Multiple Myeloma
04/28
04/32
CARTITUDE-6, NCT05257083 / 2021-003284-10: A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma

Recruiting
3
750
Europe, Canada, Japan, US, RoW
Daratumumab, Bortezomib, Lenalidomide, Dexamethasone, Cilta-cel, JNJ-68284528, Cyclophosphamide, Fludarabine
Stichting European Myeloma Network, Janssen Research & Development, LLC
Multiple Myeloma
06/33
08/40
Merz
CARTITUDE-6, NCT05257083 / 2021-003284-10: A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma

Recruiting
3
750
Europe, Canada, Japan, US, RoW
Daratumumab, Bortezomib, Lenalidomide, Dexamethasone, Cilta-cel, JNJ-68284528, Cyclophosphamide, Fludarabine
Stichting European Myeloma Network, Janssen Research & Development, LLC
Multiple Myeloma
06/33
08/40
Sandhya, M
CORAL, NCT05964335: Cough Reduction in IPF with Nalbuphine ER

Recruiting
2
160
Europe, Canada, RoW
nalbuphine ER 27 mg, Active, Placebo, nalbuphine ER 54 mg, nalbuphine ER 108 mg
Trevi Therapeutics
Idiopathic Pulmonary Fibrosis
04/25
04/25
Overbeek, M
CORAL, NCT05964335: Cough Reduction in IPF with Nalbuphine ER

Recruiting
2
160
Europe, Canada, RoW
nalbuphine ER 27 mg, Active, Placebo, nalbuphine ER 54 mg, nalbuphine ER 108 mg
Trevi Therapeutics
Idiopathic Pulmonary Fibrosis
04/25
04/25
Sanchez, J Roldan
CORAL, NCT05964335: Cough Reduction in IPF with Nalbuphine ER

Recruiting
2
160
Europe, Canada, RoW
nalbuphine ER 27 mg, Active, Placebo, nalbuphine ER 54 mg, nalbuphine ER 108 mg
Trevi Therapeutics
Idiopathic Pulmonary Fibrosis
04/25
04/25
Martínez, JM Cifrian
CORAL, NCT05964335: Cough Reduction in IPF with Nalbuphine ER

Recruiting
2
160
Europe, Canada, RoW
nalbuphine ER 27 mg, Active, Placebo, nalbuphine ER 54 mg, nalbuphine ER 108 mg
Trevi Therapeutics
Idiopathic Pulmonary Fibrosis
04/25
04/25
Villamor, M
CORAL, NCT05964335: Cough Reduction in IPF with Nalbuphine ER

Recruiting
2
160
Europe, Canada, RoW
nalbuphine ER 27 mg, Active, Placebo, nalbuphine ER 54 mg, nalbuphine ER 108 mg
Trevi Therapeutics
Idiopathic Pulmonary Fibrosis
04/25
04/25
Hudig, L
CORAL, NCT05964335: Cough Reduction in IPF with Nalbuphine ER

Recruiting
2
160
Europe, Canada, RoW
nalbuphine ER 27 mg, Active, Placebo, nalbuphine ER 54 mg, nalbuphine ER 108 mg
Trevi Therapeutics
Idiopathic Pulmonary Fibrosis
04/25
04/25
Wijsenbeek-Lourens, M
CORAL, NCT05964335: Cough Reduction in IPF with Nalbuphine ER

Recruiting
2
160
Europe, Canada, RoW
nalbuphine ER 27 mg, Active, Placebo, nalbuphine ER 54 mg, nalbuphine ER 108 mg
Trevi Therapeutics
Idiopathic Pulmonary Fibrosis
04/25
04/25
Kramer, H
CORAL, NCT05964335: Cough Reduction in IPF with Nalbuphine ER

Recruiting
2
160
Europe, Canada, RoW
nalbuphine ER 27 mg, Active, Placebo, nalbuphine ER 54 mg, nalbuphine ER 108 mg
Trevi Therapeutics
Idiopathic Pulmonary Fibrosis
04/25
04/25
Verdirosi, D
CORAL, NCT05964335: Cough Reduction in IPF with Nalbuphine ER

Recruiting
2
160
Europe, Canada, RoW
nalbuphine ER 27 mg, Active, Placebo, nalbuphine ER 54 mg, nalbuphine ER 108 mg
Trevi Therapeutics
Idiopathic Pulmonary Fibrosis
04/25
04/25
Maznikoski, M
CORAL, NCT05964335: Cough Reduction in IPF with Nalbuphine ER

Recruiting
2
160
Europe, Canada, RoW
nalbuphine ER 27 mg, Active, Placebo, nalbuphine ER 54 mg, nalbuphine ER 108 mg
Trevi Therapeutics
Idiopathic Pulmonary Fibrosis
04/25
04/25

Download Options